This research is supported by the DOE Isotope Program, managed by the DOE Office of Science for Isotope R&D and Production. These efforts advance the DOE Isotope Program and its mission to conduct research and development on new and improved isotope production and processing for high-priority, cancer-fighting radioisotopes. The results demonstrated good separation capabilities of radium from actinium along with remarkable radiopurities using relatively simple chemicals. Through rigorous screening based on separation efficiency and chemical durability, they ultimately determined that zirconium-based materials are the optimal platform. The researchers explored this new class of radiation-resistant materials with respect to the fundamental radiochemical separations of radium, actinium, and lead. This creates new sets of challenges, particularly radiation damage to process equipment. While these radioisotopes have the potential to produce powerful results in the treatment of cancers, scaling up production to meet the high demand of these radioisotopes comes with increasing radiation levels. This research by scientists at Argonne National Laboratory explored new materials that could support and facilitate the efficient separation of radium and actinium in the context of the large-scale production of radioisotopes used in targeted alpha therapy. These new resins and this recent research will help producers save time, effort, and costs while reducing the risks of manufacturing alpha-emitting radioisotopes. Chemical processes need to be robust in these hazardous environments. As production increases, radiation levels will also increase. These new types of resins will support the purification and distribution of these lifesaving isotopes. The Impactĭemand and production of actinium-225 (Ac-225) and other alpha-emitting radioisotopes are increasing. Now, researchers have investigated the use of radiation-resistant inorganic resin scaffolds as platforms for separating radium, actinium, and lead. This can destroy typical separation equipment due to a radioactive process called alpha decay. This method poses a challenge: how to chemically separate the radium from the actinium. One method of making one isotope, actinium-225, involves bombarding radium targets with neutrons. The Department of Energy (DOE) Office of Science’s Isotope Program is developing and marketing novel radioactive isotopes for targeted alpha therapy. If no settlement is reached, the EPA can a. It’s especially useful for treating metastasized cancers. Test 1 Spring 2020 5.0 (1 review) The Environmental Protection Agency (EPA) discovers that Fish Farm Inc. Targeted alpha therapy can destroy cancerous cells without harming healthy cells.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |